---
anonymous_label: OUT-37
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
output_sha256: a81aa58d8dbd182e190407ec2e99728657d72d7f80ab72f28a8d7a997b3c58be
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-37

I recommend that you commit to the **Claim File Review**.

### Reasoning and Trade-offs
You are currently facing a "false positive" signal. Your lagging indicators (bookings, renewals) look strong, but your leading indicators (adjuster behavior, health-liability abandonment) are flashing red.

The expansion bookings are heavily contaminated by "bundle pricing" (financial incentive) and the roadmap pitch (future promise), meaning you aren't measuring the value of the *product*, but rather the effectiveness of a *sales promotion*. Meanwhile, your usage spike is driven by managers doing retrospective audits—not adjusters doing real-time work.

Here is why the other options are insufficient or dangerous:
*   **Scaling Broadly:** This is a high-risk gamble. The evidence suggests that while managers like the *idea* of DraftPath, front-line adjusters (the actual users) are abandoning it. Scaling a product with low "stickiness" leads to massive churn in 12 months.
*   **Usage Quality Sprint:** This tracks *if* they use it, but not *why* or *how*. You already know the return rate is low after two days; seeing that trend on a dashboard doesn't tell you how to fix the product.
*   **Commercial Cleanroom:** This tests pricing and sales psychology, but not product-market fit. If the product is fundamentally broken for health-liability or lacks "explainability," no amount of pricing adjustment will save the renewal.
*   **Narrowing to Health-Liability:** This is premature. You have evidence that it's failing in this segment, but you don't yet know if the failure is due to a lack of features or a fundamental flaw in the AI's logic.

The **Claim File Review** is the only option that addresses the "Explainability Gap." In B2B workflow software—especially in regulated insurance—the value is not just the *correct* answer, but the *defensible* answer. If adjusters cannot explain a recommendation to a reviewer, the feature is useless regardless of its accuracy. By inspecting actual files, you move from "vanity metrics" (usage %) to "value metrics" (acceptance vs. override).

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. It provides a small sample size compared to the "big data" of a Usage Sprint or the revenue data of a Cleanroom. By choosing this, you are sacrificing **statistical certainty and speed**. You will enter the next fiscal year with a deep understanding of *why* the product fails for some, but you will not have a quantified "lift" in renewal probability to show the board.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "bundle pricing" was not the primary driver of expansion, but rather a secondary convenience. Specifically, if you found that accounts *without* the bundle were still renewing early and specifically citing DraftPath as the reason for their expansion, it would indicate that the product value is higher than the usage data suggests, and your primary risk is pricing strategy rather than product utility.
